Botulism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Botulism - Pipeline Review, H2 2016

Botulism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Botulism - Pipeline Review, H2 2016
Published Jul 20, 2016
53 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Botulism - Pipeline Review, H2 2016, provides an overview of the Botulism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Botulism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Botulism and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Botulism
- The report reviews pipeline therapeutics for Botulism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Botulism therapeutics and enlists all their major and minor projects
- The report assesses Botulism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Botulism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Botulism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying

  
Source:
Document ID
GMDHC8240IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Botulism Overview71
Therapeutics Development82
  Pipeline Products for Botulism Overview81
  Pipeline Products for Botulism Comparative Analysis91
Botulism Therapeutics under Development by Companies101
Botulism Therapeutics under Investigation by Universities/Institutes111
Botulism Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Botulism Products under Development by Companies141
Botulism Products under Investigation by Universities/Institutes151
Botulism Companies Involved in Therapeutics Development167
  CytoDel, LLC161
  Hawaii Biotech, Inc.171
  Microbiotix, Inc.181
  Molecular Targeting Technologies, Inc.191
  Nanotherapeutics, Inc.201
  Planet Biotechnology Inc.211
  XOMA Corporation221
Botulism Therapeutics Assessment239
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3217
  BoNT/A HcR4 Drug Profile321
  botulinum vaccine Drug Profile331
  botulism [serotype C] vaccine Drug Profile341
  botulism [serotypes A, B, C, D, E] vaccine Drug Profile351
  botulism [serotypes A, B] vaccine Drug Profile361
  Ctyo-111 Drug Profile371
  Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism Drug Profile381
  OSX-400 Drug Profile391
  OSX-400 Backups Drug Profile401
  Polyclonal Antibody for Botulism Drug Profile411
  Recombinant Peptides to Inhibit Botulinum Toxin for Botulism Drug Profile422
  Small Molecules for Botulism Drug Profile441
  Small Molecules to Inhibit BoNT/A LC for Botulism Drug Profile451
  Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism Drug Profile461
  XOMA-3-BB Drug Profile471
  XOMA-3AB Drug Profile481
Botulism Dormant Projects491
Botulism Discontinued Products501
Botulism Product Development Milestones511
  Featured News &Press Releases511
    May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing511
Appendix522
  Methodology521
  Coverage521
  Secondary Research521
  Primary Research521
  Expert Panel Validation521
  Contact Us521
  Disclaimer531

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Botulism - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Botulism-Pipeline-Review-H2-2016-2088-16214>
  
APA:
Global Markets Direct - Market Research. (2016). Botulism - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Botulism-Pipeline-Review-H2-2016-2088-16214>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.